Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II

Russell R. Reid, Nakshatra Roy, Jon E. Mogford, Hannah Zimmerman, Chung Lee, Thomas A. Mustoe*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Effective blockade of the pluripotent cytokine transforming growth factor (TGF)-β as a means of cutaneous scar reduction is a strategy with great potential. This desired effect may be achieved through the overexpression of mutant TGF-β receptors within the wound milieu. Our goal was to examine the effects of dominant negative mutant TGF-β receptor II (TGFβRIIdn) protein expression in a well-established rabbit ear model of hypertrophic scarring. Serial injections of a retroviral construct encoding a truncated TGFβRII and the marker green fusion protein (pMSCV-rIIdn-GFP) were performed in 7 mm punch wounds at day 10 and day 12 (two-day injection group) or days 8, 10, 12 (three-day injection group) post-wounding. Delivery of an empty vector (pMSCV-GFP) at the same time points served as a negative control. Histomorphometric analysis of wounds harvested at day 28 revealed a modest, though statistically significant reduction (20%, p = 0.027) in the scar elevation index (SEI) in two-day treated and a more modest reduction in SEI (12%) in the three-day treated arm compared to null-treated controls. Confocal microscopy confirmed stable, yet variable transfection of the construct in both peri-wound tissue as well as rabbit dermal fibroblasts transfected in vitro. Optimisation of this novel application in retroviral gene therapy could lead to effective anti-scarring strategies.

Original languageEnglish (US)
Pages (from-to)64-72
Number of pages9
JournalJournal of Plastic, Reconstructive and Aesthetic Surgery
Issue number1
StatePublished - Jan 2007


  • Gene therapy
  • Hypertrophic scarring
  • Retrovirus
  • Transforming growth factor-beta

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II'. Together they form a unique fingerprint.

Cite this